12-Year-Old Becomes First Indiana Patient to Receive FDA-Approved Gene Therapy for Beta-Thalassemia
核心洞察
Elin Lewis, a 12-year-old from Greenwood, became the first patient in Indiana to receive FDA-approved gene therapy (搜索) for transfusion-dependent beta-thalassemia (搜索) at Riley Children's Health (搜索).
Clinical data shows up to 90% of patients dependent on blood transfusions who completed the new therapy no longer required those transfusions, potentially shifting treatment from disease management to cure.
The gene therapy (搜索) works by modifying a patient's own blood stem cells (搜索) to function properly, then infusing them back to help create healthy blood cells independently.
A 12-year-old girl from Greenwood has become the first patient in Indiana to receive a groundbreaking FDA-approved gene therapy (搜索) for transfusion-dependent beta-thalassemia (搜索), marking a potential shift from disease management to cure for this rare blood disorder. Riley Children's Health (搜索) announced that Elin Lewis successfully underwent the procedure, which could eliminate her need for lifelong blood transfusions.
Breakthrough Clinical Results
The new gene therapy (搜索) has demonstrated remarkable efficacy in clinical trials, with data showing up to 90% of patients dependent on blood transfusions who completed the therapy no longer required those transfusions. This represents a significant advancement for treating beta-thalassemia (搜索), a disorder that affects approximately 1,500 people in the United States.
According to the Centers for Disease Control and Prevention (搜索), beta-thalassemia (搜索) affects the body's ability to make hemoglobin, the protein that helps carry oxygen to cells throughout the body. Patients typically require regular blood transfusions, which can cause severe side effects including fatigue, weakness, liver damage, and heart failure.
Treatment Process and Mechanism
Dr. Jonathan Bardah, a pediatric stem cell transplant physician, performed the treatment through the Riley Red Blood Cell Curative Clinic. The gene therapy (搜索) works by modifying a patient's own blood stem cells (搜索) so they function properly, then infusing those modified cells back into the patient to help create new healthy blood cells independently.
The treatment process takes several months to complete. Elin's stem cells were collected in November 2025, and she received the infusion of modified cells in February. Riley Children's Health (搜索) reports that the treatment is working as expected.
Patient and Family Impact
"This means freedom from this condition for Elin," said Monica Lewis, Elin's mother. "After years of monthly transfusions, this is truly life-changing. The entire care, from the doctors, the nurses to everyone who supported us on this journey, was incredible. Elin didn't skip a beat — she's already back on the trampoline practicing her gymnastic stunts, just being a normal kid. She has a bright, healthy future ahead of her."
Disease Background and Treatment Evolution
Beta-thalassemia (搜索) is typically inherited from parents to children and is most commonly found in people from Mediterranean countries, as well as those from Asia, Africa, and the Middle East, according to the CDC. Previous treatment options often required a donor and came with serious risks to the patient.
Riley Children's Health (搜索) emphasizes that this gene therapy (搜索) offers patients a safer curative option compared to traditional treatments. The FDA approval of this therapy represents a significant milestone in moving away from managing the disease toward potentially curing it.